Outcome study to determine the internal consistency, reproducibility, and concurrent validity of the French-Canadian version of the Scoliosis Research Society 22 (SRS-22 fcv) patient questionnaire in France.
To determine whether the SRS-22 fcv can be used in a population from France.
The SRS-22 has been translated and validated in multiple countries, notably in the French-Canadian language in Quebec, Canada. Use of SRS-22 fcv seems appropriate for evaluating adolescent idiopathic scoliosis in France. However, French-Canadian French is noticeably different from the French spoken in France, and no study has investigated the use of a French-Canadian version of a health-quality questionnaire in another French population.
The methods used for validating the SRS-22 fcv in Quebec were adopted for use with a group of 200 adolescents with idiopathic scoliosis and 60 healthy adolescents in France. Reliability and reproducibility were measured by the Cronbach α and intraclass correlation coefficient (ICC), construct validity by factorial analysis, concurrent validity by the Short-Form of the survey, and discriminant validity by analysis of variance and multivariate linear regression.
In France, the SRS-22 fcv showed good global internal consistency (Cronbach α = 0.87, intraclass correlation coefficient = 0.92), a coherent factorial structure, and high correlation coefficients between the SRS-22 fcv and Short-Form of the survey (P < 0.001). However, reliability and validity were slightly less than that for the instrument's original validation and the validation of the SRS-22 fcv in Quebec. These differences could be explained by language and cultural differences.
The SRS-22 fcv is relevant for use in France, but further development and validation of a specific French questionnaire remain necessary to improve the assessment of functional outcomes of adolescents with scoliosis in France.
Level of Evidence: N/A
The aim of this study was to assess the use of the French-Canadian version of the Scoliosis Research Society 22 (SRS-22 fcv) in France because of differences between the French-Canadian culture and the French culture in Europe. This study validated the use of the SRS-22 fcv for adolescents in France.
*Peditaric Orthopaedic Department, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris Diderot University, Paris, France; and
†Peditaric Orthopaedic Department, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.
Address correspondence and reprint requests to Guillaume Lonjon, MD, Pediatric Orthopaedic Department, Robert Debré Hospital, AP-HP, Paris-Diderot University, 48 bd Serurier, 75019 Paris, France; E-mail: firstname.lastname@example.org
Acknowledgment date: March 15, 2013. First revision date: August 10, 2013. Acceptance date: August 23, 2013.
The manuscript submitted does not contain information about medical device(s)/drug(s).
No funds were received in support of this work.
Relevant financial activities outside the submitted work: consultancy and royalties.